NLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
This is not a CAPTIS article. Originally, it was published here.
Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2...
Orex Announces Board Changes and a Grant of Options